NeoGenomics Inc (NEO) is a leading provider of cancer-focused genetic testing and information services. The company offers a comprehensive portfolio of laboratory-developed genetic tests, including tests for solid tumors, hematologic malignancies, and hereditary cancer syndromes. With its advanced technology platform and extensive expertise, NeoGenomics is at the forefront of precision medicine, helping oncologists make informed treatment decisions and improve patient outcomes.

When it comes to technical analysis, NeoGenomics Inc (NEO) offers a range of tools and indicators to assist investors in analyzing the stock's performance. One important indicator is the relative strength index (RSI), which measures the strength and speed of a stock's price movement. The RSI for NEO stock is currently at a neutral level, indicating that the stock is neither overbought nor oversold.

NeoGenomics  (NEO) Technical Analysis

Get insights into NeoGenomics Inc's (NEO) technical indicators such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Analyze and evaluate the stock using reliable technical analysis tools. Understand the market trends and make informed investment decisions. Access comprehensive technical analysis data on NEO stock.

NeoGenomics Inc (NEO) Technical Analysis: RSI, ADX, MACD, and More

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	68.90	Neutral	19.7%
auto_graphMACD	33.21	Neutral	955.9%
auto_graphCCI	181.61	Sell	261.4%
auto_graphADX	31.96	Neutral	-
auto_graphATR	65.18	Buy	-
auto_graphWILLR	-21.43	Neutral	331.4%
auto_graphROC	132.99	Neutral	609.7%
auto_graphSTOCHRSI	92.29	Sell	103.7%

Buy	1	-87.50%
Hold	5	-37.50%
Sell	2	-75.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

NeoGenomics (NEO) Technical Analysis

Keep an eye on NeoGenomics

Frequently Asked Questions

What are the technical signals for NeoGenomics (NEO) stock based on the last 30 days?

Take Your Investments to a Whole New Level